Beckman Coulter and SphingoTec Collaborate on Kidney Health Assessment

On October 9, 2024, SphingoTec GmbH announced a partnership with Beckman Coulter Diagnostics. This collaboration is set to integrate SphingoTec’s Proenkephalin 119-159 (penKid) biomarker into Beckman Coulter’s immunoassay analyzers, marking the first licensing agreement for penKid in central laboratories. This initiative aims to improve global diagnostics for acute kidney injury (AKI).

PenKid offers real-time plasma biomarker detection unaffected by inflammation, facilitating earlier detection of kidney function decline. It addresses gaps in current diagnostics, important as AKI cases are rising, affecting over 13 million people annually. Beckman Coulter will develop an automated penKid test, enhancing timely kidney health assessment.

Leaders from both companies emphasized the potential patient care benefits, citing penKid’s scientific validation and the broad reach of Beckman Coulter’s platforms. This partnership aims to provide actionable insights for clinicians worldwide, improving outcomes for patients with AKI.